An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Roche

Status: Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01790217

ML27895

Details and patient eligibility

About

This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in first-line therapy in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer. Eligible patients, for whom the treating physician has decided to initiate treatment with Tarceva according to the local label will be followed for 18 months.

Enrollment: 52 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
• Patients for whom the treating physician has decided to initiate first-line therapy with Tarceva in accordance with the Summary of Product Characteristics and local guidelines

Exclusion criteria

• N/A

Trial design

52 participants in 1 patient group

Cohort